New hope for transplant patients: easier CMV prevention on the horizon?

This study tests whether a drug called letermovir is easier to tolerate than the standard treatment for preventing CMV infection in heart and lung transplant recipients. About 80 adults who have had a heart or lung transplant will take either letermovir or the usual drug, and researchers will compare rates of CMV infection, side effects like low white blood cell counts, and how well patients stick to the medication. The goal is to find a safer, more tolerable option for long-term infection prevention after transplant.